Our Technologies

ATTWILL is developing 4 novel technology platforms: CHGLock, ATH antithrombin Heparin, HaloGuard and XirTAM3. Each technology has the ability to be disruptive both in performance and savings to health care systems. Each platform will initially be applied within the Vascular Access field where the current unresolved needs are costing health care systems billions of dollars. For applications outside Vascular Access, the technology will be out licensed.
Learn More
STERIL-flow (CHGLock™)
Learn More
Anti-thrombin Heparin (ATH)
Learn More
XirTAM3®
Learn More
HaloGuard